Close

Explore AI

Explore GPTs

Explore AI News

Explore AI Videos

Explore AI for Jobs

Latest Eli Lilly AI Videos

Find the latest for Eli Lilly company videos

Follow
... 20:5
Episode 2 - Smarter AI: Transforming India

ETCIO

1+ months ago 6K views

AI is transforming healthcare through advancements in diagnostics, personalized medicine, and drug discovery. Lenovo is integrating AI into medical imaging to improve disease detection and enhance the efficiency of diagnostics. Apollo 24/7 leverages AI technologies to enhance patient outcomes and manage chronic conditions better. AI's capacity for predictive analytics allows for tailored treatment regimens, significantly impacting patient care. Both companies emphasize the importance of ethical AI deployment in healthcare, ensuring responsible use amidst a complex regulatory landscape. The ongoing AI revolution in healthcare promises to drive innovations and improve accessibility across India.
06:54 - 07:07

Predictive analytics are personalizing treatments and improving health outcomes.

Lenovo ISG Machine Learning Research & Innovations
... 14:18
AI Gold Rush in Pharma Marketing: Hype or Game-Changer?

Viseven

1+ months ago 2K views

AI is revolutionizing pharmaceutical marketing by enhancing efficiency and strategic capabilities. While many solutions focus on content automation, they often neglect the critical aspect of strategy, which is essential for compliance in a highly regulated industry. Effective AI-enabled solutions should prioritize creating modular and reusable content that aligns with regulatory requirements, thereby speeding up the marketing review process. The future success of companies in this sector depends on their ability to blend AI capabilities with true strategic planning rather than simply increasing speed of content production.
05:40 - 05:55

Struggles with compliance bottlenecks persist despite AI's promise in speeding up reviews.

Machine Learning Healthcare
... 13:50
IDOLpro: Generative AI for Chemistry | Tech talk with Amit Kadan

SandboxAQ

1+ months ago 2K views

IDOLpro combines AI and physics to enhance drug design by generating small molecules tailored for specific protein targets. Traditional methods are time-consuming, as they require evaluating vast chemical libraries. In contrast, IDOLpro uses generative AI to jump directly to relevant chemical spaces, optimizing for properties like synthetic accessibility and binding affinity. The framework employs a diffusion model guided by machine learning and physics-based scoring functions, significantly improving the efficiency of drug discovery. Initial evaluations show IDOLpro outperformed existing methods in generating viable drug candidates with desirable properties.
04:00 - 04:04

Iterative grading in IDOLpro enhances molecular properties like binding affinity.

SandboxAQ Machine Learning Research & Innovations
... 8:19
Buffett’s Record Cash Pile | Bro Code-Maker's Big Bet | India's Agentic AI | Top 5 News

Mint

1+ months ago 1K views

Indo Beverages aims to double its revenue to 700 crore rupees by FY 26, focusing on innovative products like herbal liquor Bonga Bonga and upcoming whiskey launches. Berkshire Hathaway has reached record cash reserves while Warren Buffett remains cautious about market valuations, focusing on equity investing. Indian venture capitalists are channeling funds into agentic AI, which operates with minimal human input, leading to predictions of significant market growth. Furthermore, Indian Bank's CEO is shifting focus to micro small and medium enterprises, while Gentari is investing in green hydrogen technologies to support India's clean energy transition.
Big Data Analytics Finance
... 8:29
IPA Stock - AI Company to Watch (Update)

Blaze Capital

1+ months ago 10K views

Immuno Precise Antibodies (IPA), listed on NASDAQ as IPA, aims to revolutionize healthcare and drug discovery through its patented Lens AI technology. With over 90% of clinical drug developments failing, IPA addresses this challenge by accelerating drug discovery and integrating artificial intelligence with biological data. Their HFT patterns program introduces unique signature sequences, enabling the harmonization of complex biological data. The potential market for AI in drug discovery is projected to be worth $24.6 billion by 2029. The company is making strides in developing precision-targeted treatments, particularly for cancer, enhancing drug efficacy with fewer side effects.
04:01 - 04:06

In silico antibodies targeting tumor proteins show AI's efficacy in drug development.

Immunoprecise Antibodies Ltd Finance
... 10:35
Big Bear AI is the NEXT PALANTIR! Technical/Fundamental Analysis of BBAI Stock

Green Money Momentum

1+ months ago 2K views

Big Bear AI's stock has experienced notable fluctuations, currently showing 166% gains over the past month and 41% over three months. Recent price movements have raised questions about potential pullbacks or if new all-time highs will be reached. Technical and fundamental analysis suggests significant interest from both retail and institutional investors, including major firms like BlackRock and Vanguard. The CEO's recent insider purchases reflect confidence in the company's future, particularly after winning a key Department of Defense contract. Upcoming earnings reports could further influence stock dynamics.
03:41 - 03:48

CEO Kevin's significant share acquisition demonstrates insider confidence in Big Bear AI.

BigBearAi Big Data Analytics Finance
... 10:30
Tempus AI & Palantir Stock Are SHOCKING The Market!

Data Dispatch

1+ months ago 6K views

Tempest AI's stock surged to $72 from $40 after acquiring Ambry Genetics for $600 million, boosting market confidence. Analysts are raising price targets, now averaging $63.12, with a high of $74. Meanwhile, Palantir remains steady above $100 amid discussions on valuation and potential government contracts, emphasizing its role in defense. The broader market exhibits resilience, with significant gains noted despite minor tariff uncertainties and mixed earnings reports from major players. Commentary on AI's critical role in these developments highlights the ongoing transformation within the industry and investor sentiment.
06:54 - 07:05

Palantir emphasizes AI in defense, boosting its market position.

Tempus AI Finance
... 9:14
Investors "Parsing Out" A.I. Winners, NVDA, PLTR & OKLO Among Them

Schwab Network

1+ months ago 11K views

Market strategist Marc Lopresti discusses recent pullbacks in major tech stocks, particularly focusing on Google and AMD. Despite Alphabet's strong earnings and sales growth, concerns about high spending in AI development have affected investor sentiment. Smart investors are buying the dips, anticipating that significant corrections in valuable AI stocks could lead to future profitability. Lopresti emphasizes the need to analyze which companies will emerge as winners in the AI arms race, aligning investment strategies with market trends and valuations. Overall, the conversation highlights active trading tactics amid uncertain market conditions.
03:00 - 03:09

Possible profit-taking in oversold AI stocks signals market volatility and investor caution.

NVDA Machine Learning Finance
... 9:14
Investors "Parsing Out" A.I. Winners, NVDA, PLTR & OKLO Among Them

Schwab Network

1+ months ago 11K views

Market strategist Marc Lopresti discusses recent pullbacks in major tech stocks, particularly focusing on Google and AMD. Despite Alphabet's strong earnings and sales growth, concerns about high spending in AI development have affected investor sentiment. Smart investors are buying the dips, anticipating that significant corrections in valuable AI stocks could lead to future profitability. Lopresti emphasizes the need to analyze which companies will emerge as winners in the AI arms race, aligning investment strategies with market trends and valuations. Overall, the conversation highlights active trading tactics amid uncertain market conditions.
03:00 - 03:09

Possible profit-taking in oversold AI stocks signals market volatility and investor caution.

NVDA Machine Learning Finance